Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Carsgen Life Sciences Co. Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by a distinct examiner, TRAN, KHOA NHAT, who is the busiest examiner for the portfolio with 1 pending action. This singular focus indicates that the company's current prosecution efforts are concentrated on a specific set of claims within a single technical domain. The applicant can tailor their arguments to the specific scientific expertise of this examiner.
The fact that the portfolio is limited to a distinct art unit suggests a narrow technical scope for the pending application. Since there is a distinct examiner involved, the applicant can tailor their communication and legal arguments specifically to the preferences of TRAN, KHOA NHAT. This centralized approach simplifies the management of the pending office action and allows for a consistent strategy without the need to reconcile different examiner viewpoints. It also minimizes the risk of inconsistent claim interpretations across the portfolio.
In the Biotechnology & Pharmaceuticals sector, where examination can be complex, having a solitary pending office action allows for a highly focused response. The distinct art unit involved provides a stable environment for the prosecution of the company's intellectual property. By addressing the concerns of the examiner currently assigned to the case, the company can efficiently move toward a resolution for its active patent application. This targeted strategy is effective for securing critical biotechnology assets.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 1 | 43.2% | +53.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623481 | CELL FOR RESISTING TRANSPLANT REACTION AND METHOD | TRAN, KHOA NHAT | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17623481 | CELL FOR RESISTING TRANSPLANT REACTION AND METHOD | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 4d overdue | Pending | Dec 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial